C D Furberg

Summary

Affiliation: Wake Forest University School of Medicine
Country: USA

Publications

  1. ncbi Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned
    Curt D Furberg
    Wake Forest University School of Medicine, Winston Salem, NC 27157 1063, USA
    Circulation 105:917-22. 2002
  2. ncbi Approaches to data analyses of clinical trials
    Curt D Furberg
    Division of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, NC, USA
    Prog Cardiovasc Dis 54:330-4. 2012
  3. ncbi Five years of Trials
    Douglas G Altman
    Centre for Statistics in Medicine, Wolfson College Annexe, Linton Road, Oxford OX2 6UD, UK
    Trials 12:248. 2011
  4. ncbi A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization
    Elsayed Z Soliman
    Division of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, NC, USA
    Trials 12:3. 2011
  5. ncbi [Reduce prescription of expensive drugs without increased value]
    Curt Furberg
    Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, USA
    Lakartidningen 100:4113. 2003
  6. ncbi [Alfadil--positive documentation when it comes to safety is missing]
    Curt Furberg
    Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, USA
    Lakartidningen 100:4329; discussion 4330. 2003
  7. ncbi Doxazosin, an inferior antihypertensive agent?
    C D Furberg
    Department of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, NC, USA
    J Hum Hypertens 16:375-7. 2002
  8. ncbi To whom do the research findings apply?
    Curt D Furberg
    Department of Public Health Sciences, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157 1063, USA
    Heart 87:570-4. 2002
  9. ncbi The FDA and drug safety: a proposal for sweeping changes
    Curt D Furberg
    Department of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Arch Intern Med 166:1938-42. 2006
  10. ncbi Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study
    Curt D Furberg
    Division of Public Health Sciences, School of Medicine, Wake Forest University, Winston Salem, North Carolina 27157 1063, USA
    J Am Geriatr Soc 56:792-9. 2008

Detail Information

Publications78

  1. ncbi Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned
    Curt D Furberg
    Wake Forest University School of Medicine, Winston Salem, NC 27157 1063, USA
    Circulation 105:917-22. 2002
    ..We analyzed the HERS data to determine whether there were specific subgroups of women who responded differently to treatment, either during the first year or in the overall study...
  2. ncbi Approaches to data analyses of clinical trials
    Curt D Furberg
    Division of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, NC, USA
    Prog Cardiovasc Dis 54:330-4. 2012
    ..four questions related to secondary analysis with emphasis on sharing of data primarily from NIH-sponsored trials: Who has access to this information? What questions can be asked? What are the requirements? What are the common challenges?..
  3. ncbi Five years of Trials
    Douglas G Altman
    Centre for Statistics in Medicine, Wolfson College Annexe, Linton Road, Oxford OX2 6UD, UK
    Trials 12:248. 2011
    ..These include the publication of raw data, extended versions of previously published trial-related articles, descriptions of 'lessons learned', negative results, and educational articles regarding ethics and reporting bias...
  4. ncbi A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization
    Elsayed Z Soliman
    Division of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, NC, USA
    Trials 12:3. 2011
    ..More information is needed regarding the efficacy in reducing the risk factors of cardiovascular disease (CVD), side effects, improvement in adherence and physician/patient "acceptability" of the Polypill...
  5. ncbi [Reduce prescription of expensive drugs without increased value]
    Curt Furberg
    Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, USA
    Lakartidningen 100:4113. 2003
  6. ncbi [Alfadil--positive documentation when it comes to safety is missing]
    Curt Furberg
    Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, USA
    Lakartidningen 100:4329; discussion 4330. 2003
  7. ncbi Doxazosin, an inferior antihypertensive agent?
    C D Furberg
    Department of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, NC, USA
    J Hum Hypertens 16:375-7. 2002
  8. ncbi To whom do the research findings apply?
    Curt D Furberg
    Department of Public Health Sciences, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157 1063, USA
    Heart 87:570-4. 2002
  9. ncbi The FDA and drug safety: a proposal for sweeping changes
    Curt D Furberg
    Department of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Arch Intern Med 166:1938-42. 2006
    ....
  10. ncbi Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study
    Curt D Furberg
    Division of Public Health Sciences, School of Medicine, Wake Forest University, Winston Salem, North Carolina 27157 1063, USA
    J Am Geriatr Soc 56:792-9. 2008
    ....
  11. ncbi Double-blindness protects scientific validity
    C D Furberg
    Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1063, USA
    J Thromb Haemost 6:230-1. 2008
  12. ncbi Are all angiotensin-converting enzyme inhibitors interchangeable?
    C D Furberg
    Department of Public Health Sciences, Wake Forest University, Winston Salem, North Carolina 27157, USA
    J Am Coll Cardiol 37:1456-60. 2001
    ..For our patients, such practice is a legitimate expectation. Therefore, it seems prudent to recommend that patients requiring ACE inhibitor therapy be prescribed one that has been proven effective and safe...
  13. ncbi Should evidence-based proof of drug efficacy be extrapolated to a "class of agents"?
    Curt D Furberg
    Department of Public Health Sciences, Wake Forest University School of Medicine, Medical Center Blvd, Winston Salem, NC 27157 1063, USA
    Circulation 108:2608-10. 2003
  14. ncbi Isradipine in prediabetic hypertensive subjects
    R P Byington
    Department of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1063, USA
    Diabetes Care 21:2103-10. 1998
    ....
  15. ncbi Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes
    M Pahor
    Sticht Center on Aging, Department of Internal Medicine, Wake Forest University, Winston Salem, North Carolina 27157, USA
    Diabetes Care 23:888-92. 2000
    ..To assess whether ACE inhibitors are superior to alternative agents for the prevention of cardiovascular events in patients with hypertension and type 2 diabetes...
  16. ncbi Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials
    M Pahor
    Sticht Center on Aging, Department of Internal Medicine, Wake Forest University, Winston Salem, NC 27157, USA
    Lancet 356:1949-54. 2000
    ..The aim of this meta-analysis was to compare the effects of calcium antagonists and other antihypertensive drugs on major cardiovascular events...
  17. ncbi Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials
    David L Mount
    Wake Forest University School of Medicine, Winston Salem, NC, USA
    Clin Trials 6:416-29. 2009
    ..Comparing findings from separate trials is necessary to choose among treatment options, however differences among study cohorts may impede these comparisons...
  18. ncbi Usefulness of T-axis deviation as an independent risk indicator for incident cardiac events in older men and women free from coronary heart disease (the Cardiovascular Health Study)
    P M Rautaharju
    Department of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
    Am J Cardiol 88:118-23. 2001
    ..These results suggest that T-axis deviation is an easily quantified marker for subclinical disease and an independent indicator for the risk of incident CHD events in older men and women free of CHD...
  19. ncbi Clinical Implications of Recent Findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Other Studies of Hypertension
    C D Furberg
    Department of Public Health Sciences, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157 1063, USA
    Ann Intern Med 135:1074-8. 2001
    ....
  20. ncbi Assessment of temporal bias in longitudinal measurements of carotid intimal-medial thickness in the Asymptomatic Carotid Artery Progression Study (ACAPS). ACAPS Research Group
    W A Riley
    Department of Neurology, Bowman Gray School of Medicine, Wake Forest University, Winston Salem, NC 27157 1078, USA
    Ultrasound Med Biol 22:405-11. 1996
    ..The carotid IMT measurement process, when combined with uniform reader training, certification and monitoring of reading performance throughout the course of the study, can avoid the temporal bias observed in other studies...
  21. ncbi Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis
    Sonal Singh
    Department of Medicine, One Medical Center Blvd, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    JAMA 300:1439-50. 2008
    ..Inhaled anticholinergics (ipratropium bromide or tiotropium bromide) are widely used in patients with chronic obstructive pulmonary disease (COPD) but their effect on the risk of cardiovascular outcomes is unknown...
  22. ncbi Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis
    Sonal Singh
    Department of Medicine, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    JAMA 298:1189-95. 2007
    ..Recent reports of serious adverse events with rosiglitazone use have raised questions about whether the evidence of harm justifies its use for treatment of type 2 diabetes...
  23. ncbi Thiazolidinediones and heart failure: a teleo-analysis
    Sonal Singh
    Section of General Internal Medicine, Wake Forest University School of Medicine, 1 Medical Center Blvd, Winston Salem, NC 27157, USA
    Diabetes Care 30:2148-53. 2007
    ..We aimed to evaluate the magnitude of the risk of heart failure with TZDs and classify this adverse effect under the novel dose-time-susceptibility system...
  24. ncbi Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy
    Robert P Byington
    Wake Forest University School of Medicine, Winston Salem, NC 27157 1063, USA
    Arterioscler Thromb Vasc Biol 22:1692-7. 2002
    ..In addition to the events trial, a carotid ultrasound substudy was established in 1993 to be conducted concurrently to determine whether hormone therapy affects the progression of the underlying atherosclerotic process...
  25. ncbi Effect of Ginkgo biloba on blood pressure and incidence of hypertension in elderly men and women
    Tina E Brinkley
    Sticht Center on Aging, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
    Am J Hypertens 23:528-33. 2010
    ..Accumulating evidence suggests that Ginkgo biloba is cardioprotective, in part, through its vasodilatory and antihypertensive properties. However, definitive data on its blood pressure (BP)-lowering effects in humans is lacking...
  26. ncbi Controlling prescription drug expenditures: a report of success
    David P Miller
    General Internal Medicine, Wake Forest University Health Sciences, Winston Salem, NC 27157, USA
    Am J Manag Care 13:473-80. 2007
    ..To determine whether a multi-interventional program can limit increases in prescription drug expenditures while maintaining utilization of needed medications...
  27. ncbi Cost-minimization and the number needed to treat in uncomplicated hypertension
    K A Pearce
    Department of Family and Community Medicine, Bowman Gray School of Medicine, Winston-Salem, North Carolina 27012, USA
    Am J Hypertens 11:618-29. 1998
    ..Treatment costs to prevent major hypertensive complications are much lower with diuretics and beta-blockers than with ACEI, CCB, or alpha-blockers, especially in middle-aged patients...
  28. ncbi Developing an optimal approach to global drug safety
    R Balkrishnan
    Department of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Intern Med 250:271-9. 2001
    ..This report summarizes the resulting discussions of global postmarketing surveillance initiatives and describes efforts to reduce medication errors, and improve global communication about drug safety...
  29. ncbi Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group
    R P Byington
    Department of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, NC 27157 1063, USA
    Circulation 100:e14-7. 1999
    ..Few clinical trials have documented the efficacy of preventive treatment in asymptomatic women...
  30. ncbi Comparison of mortality risk for electrocardiographic abnormalities in men and women with and without coronary heart disease (from the Cardiovascular Health Study)
    Pentti M Rautaharju
    the Department of Public Health Sciences, Wake Forest University, Winston Salem, North Carolina, USA
    Am J Cardiol 97:309-15. 2006
    ..In conclusion, we found no evidence that the relative risk of mortality for ECG abnormalities is lower in women than in men...
  31. ncbi The evolution of public health sciences in an academic medical center
    Gregory L Burke
    Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1063, USA
    South Med J 95:1248-53. 2002
  32. ncbi Attempted control of hyperglycemia during cardiopulmonary bypass fails to improve neurologic or neurobehavioral outcomes in patients without diabetes mellitus undergoing coronary artery bypass grafting
    John Butterworth
    Department of Anesthesiology, Wake Forest University School of Medicine, Winston Salem, NC 27157 1009, USA
    J Thorac Cardiovasc Surg 130:1319. 2005
    ....
  33. ncbi COX-2 inhibitors--lessons in drug safety
    Bruce M Psaty
    N Engl J Med 352:1133-5. 2005
  34. ncbi Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
    John D Brunzell
    Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, and the Northwest Lipid Laboratory, University of Washington, Seattle, Washington, USA
    Diabetes Care 31:811-22. 2008
  35. ncbi Parecoxib, valdecoxib, and cardiovascular risk
    Curt D Furberg
    Circulation 111:249. 2005
  36. ncbi Rosiglitazone and cardiovascular risk
    Bruce M Psaty
    N Engl J Med 356:2522-4. 2007
  37. ncbi Recent trials in hypertension: compelling science or commercial speech?
    Bruce M Psaty
    Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, USA
    JAMA 295:1704-6. 2006
  38. ncbi Characteristics and baseline clinical predictors of future fatal versus nonfatal coronary heart disease events in older adults: the Cardiovascular Health Study
    Camille A Pearte
    Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    Circulation 113:2177-85. 2006
    ..Although >80% of annual coronary heart disease (CHD) deaths occur in adults aged >65 years and the population is aging rapidly, CHD event fatality and its predictors in the elderly have not been well described...
  39. ncbi Long-term and short-term changes in antihypertensive prescribing by office-based physicians in the United States
    Randall S Stafford
    Program on Prevention Outcomes and Practices, Stanford Prevention Research Center, Stanford University, Palo Alto, California, USA
    Hypertension 48:213-8. 2006
    ..The recorded long- and short-term trends indicate that evidence-based clinical recommendations had an impact on antihypertensive prescribing practices, but the magnitude of impact may be smaller and of more limited duration than desired...
  40. ncbi Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Paul A Heidenreich
    VA Palo Alto Health Care System, Palo Alto, CA, USA
    J Gen Intern Med 23:509-16. 2008
    ..To evaluate the cost-effectiveness of first-line treatments for hypertension...
  41. ncbi Weight loss, muscle strength, and angiotensin-converting enzyme inhibitors in older adults with congestive heart failure or hypertension
    Gina D Schellenbaum
    Department of Epidemiology, University of Washington, Seattle, Washington, USA
    J Am Geriatr Soc 53:1996-2000. 2005
    ..To determine whether angiotensin-converting enzyme (ACE) inhibitor use may be associated with weight maintenance and sustained muscle strength (measured by grip strength) in older adults...
  42. ncbi Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors
    Frank M Sacks
    Nutrition Department, Harvard School of Public Health F M S, Boston, Mass 02115, USA
    Circulation 105:1424-8. 2002
    ..We conducted exploratory analyses of participant characteristics, lipid risk factors, and risk reduction in this group...
  43. ncbi The record on rosiglitazone and the risk of myocardial infarction
    Bruce M Psaty
    N Engl J Med 357:67-9. 2007
  44. ncbi Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)
    Paul L Canner
    Maryland Medical Research Institute, 600 Wyndhurst Avenue, Baltimore, MD 21210, USA
    Am J Cardiol 95:254-7. 2005
    ..Cardiovascular and total mortality outcomes in the niacin and placebo groups are presented by baseline glycemic status and by change in glycemic status from baseline to year 1...
  45. ncbi Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis
    Bruce M Psaty
    Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, USA
    JAMA 292:2622-31. 2004
    ..As a result, the challenge of early detection has largely shifted to the US postmarketing systems...
  46. ncbi Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study
    W T Longstreth
    Department of Neurology, University of Washington, Seattle, USA
    Stroke 33:2376-82. 2002
    ..MRI-defined infarcts are common in the elderly. We sought to explore incidence, manifestations, and predictors of such infarcts...
  47. ncbi Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study
    Bruce M Psaty
    Cardiovascular Health Research Unit, Department of Medicine, University of Washington, 1730 Minor Ave, Suite 1360, Seattle, WA 98101, USA
    Arch Intern Med 162:2325-32. 2002
    ..More widespread use of these agents will be an important intervention to prevent the devastating complications of hypertension, including stroke, myocardial infarction, and heart failure...
  48. ncbi Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency
    Michael G Shlipak
    Department of Medicine, University of California, San Francisco, and the Veterans Affairs Medical Center, San Francisco 94121, USA
    Circulation 107:87-92. 2003
    ..Little is known about the association of renal insufficiency with inflammatory and procoagulant markers, which are potential mediators for the cardiovascular risk of kidney disease...
  49. ncbi Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study
    Eric Vittinghoff
    University of California, San Francisco and Veterans Affairs Medical Center, San Francisco, 74 New Montgomery, Suite 600, San Francisco, California 94105, USA
    Ann Intern Med 138:81-9. 2003
    ..Established drugs for secondary prevention, including aspirin, beta-blockers, and lipid-lowering agents, are underused in these women, especially those at highest risk...
  50. ncbi Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis
    Bruce M Psaty
    Department of Medicine, University of Washington, Seattle, USA
    JAMA 289:2534-44. 2003
    ..Establishing relative benefit or harm from specific antihypertensive agents is limited by the complex array of studies that compare treatments. Network meta-analysis combines direct and indirect evidence to better define risk or benefit...
  51. ncbi Differences in medical care and disease outcomes among black and white women with heart disease
    Ashish K Jha
    Division of General Medicine, San Francisco VA Medical Center, San Francisco, USA
    Circulation 108:1089-94. 2003
    ..We sought to evaluate differences in medical care and clinical outcomes among black and white women with established coronary artery disease...
  52. ncbi Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002
    Randall S Stafford
    Stanford Prevention Research Center, Stanford University, Stanford, Calif 94305, USA
    JAMA 291:54-62. 2004
    ..Research on factors that influence prescribing patterns and the extent of change produced by clinical trial findings is limited...
  53. ncbi Creatinine levels and cardiovascular events in women with heart disease: do small changes matter?
    Michael G Shlipak
    General Internal Medicine Section, Veterans Affairs Medical Center, San Francisco, CA 94121, USA
    Am J Kidney Dis 43:37-44. 2004
    ....
  54. ncbi Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction
    Robert C Kaplan
    Department of Epidemiology and Social Medicine, Albert Einstein College of Medicine, Belfer Building, Room 1308C, Bronx, NY 10461, USA
    J Clin Epidemiol 55:654-64. 2002
    ..Finally, high creatinine was a strong, independent predictor of a variety of adverse outcomes after first MI...
  55. ncbi Beyond hypertension toward guidelines for cardiovascular risk reduction
    Massimo Volpe
    Department of Cardiology, II Faculty of Medicine, University of Rome La Sapienza Rome, Rome, Italy
    Am J Hypertens 17:1068-74. 2004
    ..We propose that global risk should be used as the main determinant of whom to treat, how to treat, and how much to treat...
  56. ncbi Risk of congestive heart failure in an elderly population treated with peripheral alpha-1 antagonists
    Chris L Bryson
    VA Puget Sound Health Services Research and Development, VAMC, Seattle, Washington 98108, USA
    J Am Geriatr Soc 52:1648-54. 2004
    ....
  57. ncbi Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation
    John D Brunzell
    Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, Northwest Lipid Laboratory, University of Washington, Seattle, Washington, USA
    J Am Coll Cardiol 51:1512-24. 2008
  58. ncbi Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment t
    Barry R Davis
    The University of Texas School of Public Health, 1200 Herman Pressler Street, Houston, TX 77030, USA
    Ann Intern Med 137:313-20. 2002
    ..Sixty-eight percent (6167 of 9061) of the former patients and 59% (9081 of 15 256) of the latter patients were given additional medications to achieve a target blood pressure of less than 140/90 mm Hg...
  59. ncbi Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies
    Bruce M Psaty
    JAMA 292:43-4. 2004
  60. ncbi ALLHAT: setting the record straight
    Barry R Davis
    The University of Texas Health Science Center at Houston School of Public Health, Houston, Texas 77030, USA
    Ann Intern Med 141:39-46. 2004
    ....
  61. ncbi Medications and cardiovascular health in older adults: room for improvement in prevention and treatment
    Caroline S Rhoads
    Department of Medicine, University of Washington, Seattle, WA 98101, USA
    Am J Geriatr Cardiol 13:161-7. 2004
  62. ncbi Age as a modifiable risk factor for cardiovascular disease
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, Royal Victoria Hospital, Montreal, Quebec, Canada
    Lancet 371:1547-9. 2008
  63. ncbi Serious adverse drug events reported to the Food and Drug Administration, 1998-2005
    Thomas J Moore
    Institute for Safe Medication Practices, 1800 Byberry Rd, Ste 810, Huntingdon Valley, PA 19006, USA
    Arch Intern Med 167:1752-9. 2007
    ..The US Food and Drug Administration has operated the Adverse Event Reporting System since 1998. It collects all voluntary reports of adverse drug events submitted directly to the agency or through drug manufacturers...
  64. ncbi Lipoprotein-associated phospholipase A2 and risk of venous thrombosis in older adults
    Nels Olson
    Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont, USA
    Am J Hematol 83:524-7. 2008
    ..Results were robust to several definitions of low or high Lp-PLA2. While the association of Lp-PLA(2) levels with arterial disease events implies a role for this enzyme in atherogenesis, our findings suggest that it is not prothrombotic...
  65. ncbi Calcium channel blocker use and gastrointestinal tract bleeding among older adults
    Robert C Kaplan
    Age Ageing 31:217-8. 2002
  66. ncbi Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study
    John S Gottdiener
    St Francis Hospital, Roslyn, New York Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 137:631-9. 2002
    ..Most persons with congestive heart failure are elderly, and many elderly persons with congestive heart failure have normal left ventricular systolic function...
  67. ncbi Cardiovascular disease risk status in elderly persons with renal insufficiency
    Michael G Shlipak
    General Internal Medicine Section, Medical Service, Veterans Affairs Medical Center 111A1, 4150 Clement Street, San Francisco, CA 94121, USA
    Kidney Int 62:997-1004. 2002
    ..We determined the prevalence of elevated cardiovascular disease risk status among elderly persons with renal insufficiency...
  68. ncbi Post hoc analysis of coronary findings from the prospective randomized evaluation of the vascular effects of the Norvasc trial (PREVENT)
    G B John Mancini
    Vancouver Hospital, Vancouver, BC, Canada
    Am J Cardiol 89:1414-6. 2002
  69. ncbi From knowledge to practice in chronic cardiovascular disease: a long and winding road
    Sumit R Majumdar
    Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    J Am Coll Cardiol 43:1738-42. 2004
    ..outline which of the strategies for translating evidence into clinical care have been shown to be ineffective, which strategies have been shown to be effective and to describe some untested approaches that hold promise...
  70. ncbi The PROGRESS trial: questions about the effectiveness of angiotensin converting enzyme inhibitors. Perindopril pROtection aGainst REcurrent Stroke Study
    Bruce M Psaty
    Am J Hypertens 15:472-4. 2002
  71. ncbi The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The Cardiovascular Health Study
    Bruce M Psaty
    Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology and Health Services, University of Washington, Seattle, Washington 98101, USA
    J Am Geriatr Soc 52:1639-47. 2004
    ..To assess the association between lipid levels and cardiovascular events in older adults...
  72. ncbi Contemplating ACTION--long-acting nifedipine in stable angina
    Bruce M Psaty
    Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA 98101, USA
    Lancet 364:817-8. 2004
  73. ncbi Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project)
    Paul L Canner
    Maryland Medical Research Institute, Baltimore, Maryland, USA
    Am J Cardiol 97:477-9. 2006
    ..86) in those without the MS (Z for interaction = 0.06, indicating homogeneity of the treatment effect across groups). In conclusion, these results support the use of niacin in postinfarction patients with and without the MS...
  74. ncbi Evaluating professional performance in cardiovascular medicine
    Robert D Furberg
    Evid Based Cardiovasc Med 10:75-8. 2006
  75. ncbi Adverse cardiovascular effects of rofecoxib
    Curt D Furberg
    N Engl J Med 355:204; author reply 204-5. 2006
  76. ncbi The COX-2 inhibitors--an update
    Curt D Furberg
    Am Heart J 152:197-9. 2006
  77. ncbi Recruitment of the elderly into a pharmacologic prevention trial: the Ginkgo Evaluation of Memory Study experience
    Annette L Fitzpatrick
    Department of Epidemiology, University of Washington, Seattle, WA 98115, USA
    Contemp Clin Trials 27:541-53. 2006
    ..Information on the experience of the GEM Study recruitment may be helpful to other clinical trials attempting to randomize older adults into prevention trials...
  78. ncbi Hypertension guidelines: criteria that might make them more clinically useful
    Michael H Alderman
    Department of Epidemiology and Social Medicine, Albert Einstein College of Medicine, Bronx, New York, USA
    Am J Hypertens 15:917-23. 2002
    ..Similarly, the benefit of therapy must be assessed by reduction in cardiovascular disease morbidity and mortality...